Guggenheim Maintains Ionis Pharmaceuticals Buy Rating, Adjusts Price Target
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
Stocks · News reference
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Torex Resources (NYSE: TXR) has officially listed on the New York Stock Exchange, with CEO Andrew Snowden participating in the opening bell ceremony.
Ionis Pharmaceuticals and its partner Biogen reported new two-year data from the Phase 2 CELIA study showing clinical benefit for diranersen in early Alzheimer's disease.
The European Commission has authorized TRYNGOLZA™ (olezarsen) as an adjunct to diet and lipid-lowering therapies for adult patients with severe hypertriglyceridemia.
10x Genomics has entered into two new research collaborations with Charité – Universitätsmedizin Berlin, the German Rheumatology Research Center Berlin (DRFZ), and Seoul National University to identify blood-based biomarkers for autoimmune diseases.